- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02144376
MRI and Microbiota Analysis in Constipation (MIMIC)
Validation of Magnetic Resonance Imaging to Characterise Gastrointestinal Physiology, Gut Luminal Content and Its Interaction With Colonic Microbiota in Patients With Chronic Constipation
The purpose of the study is to test how well magnetic resonance imaging (MRI) can measure whole gut transit time in people with constipation, and how readily it can detect a change in transit time induced by taking a dietary supplement with laxative effects.The investigators expect to demonstrate that ispaghula (psyllium) accelerates movement of matter through the intestinal tract.
The investigators will also assess whether a change in gut bacteria and the chemicals that they release can be detected.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom, NG7 2UH
- Nottingham University Hospitals NHS Trust
-
Nottingham, United Kingdom, NG7 2UH
- University of Nottingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meets Rome III Criteria for diagnosis of Functional Constipation5 on questionnaire (NB. Both those who do and do not meet IBS criteria will be eligible)
- At least one bowel motion per week while taking usual laxatives
- Able to give informed consent
- Aged 18 or older
Exclusion Criteria:
- History declared by the candidate of other pre-existing gastrointestinal disorder, including but not limited to:
- Inflammatory Bowel Disease
- Coeliac Disease diagnosed in the last year
- Pancreatitis
- Cancer of the gastrointestinal tract
- Any reported history of gastrointestinal resection (excluding appendicectomy or cholecystectomy)
- Presence of an intestinal stoma
- Pregnancy declared by candidate (no formal testing)
- Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury
- Reported alcohol intake of >28 units/ week with daily drinking
- Any use of a product containing ispaghula or psyllium in the 4 weeks prior to consent
- Unable to avoid use of dihydrocodeine or morphine during the study
- If taking other regular opiates such as codeine, fentanyl or Oxycodone, participants should be able to maintain a stable dose throughout the study
- Any reported history of hypersensitivity or significant adverse reaction to ispaghula, maltodextrin or bisacodyl
- Unable to stop drugs and other agents used primarily for their laxative effect, during periods of screening, washout, baseline and treatment (maximum 15 days - rescue medication will be provided).
- Antibiotic or prescribed probiotic treatment in the past 4 weeks
- Inability to lie flat or exceed scanner limits of weight <120kg
- Poor understanding of English language
- Participation in any medical trials for the past 3 months
- Any condition where the candidate is likely to require a course of antibiotics in the next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract infection, lower limb ulceration
- Judgement by the PI that the candidate who will be unable to comply with the full study protocol e.g. Diabetes, severe COPD
During the screening 2 weeks off laxatives
- No bowel motions recorded during screening period
- ≥3 complete spontaneous bowel motions (CSBMs - bowel motion with the feeling of complete evacuation, without the use of rescue therapy in the preceding 24 hours) per week
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Maltodextrin
7 days without use of laxatives other than standardised rescue therapy 7 grams maltodextrin taken 3 times daily, at least 4 hours apart, for up to 7 days
|
|
ACTIVE_COMPARATOR: Ispaghula
7 days without use of laxatives other than standardised rescue therapy 7 grams ispaghula/ psyllium taken 3 times daily, at least 4 hours apart, for up to 7 days
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weighted Average Position Score of transit marker capsules as determined by MRI
Time Frame: 24 hours after ingestion
|
After 4 days of study product participants will ingest 5 transit mark capsules, the use of which has been shown to measure whole gut transit in a similar manner to more established techniques.
They will continue to take study product before undergoing an MRI scan to assess capsule position
|
24 hours after ingestion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weighted Average Position Score of 5 transit marker capsules, as determined by MRI
Time Frame: 48 hours after ingestion
|
After 4 days of study product participants will ingest 5 transit mark capsules, the use of which has been shown to measure whole gut transit in a similar manner to more established techniques.
They will continue to take study product before undergoing an MRI scan to assess capsule position
|
48 hours after ingestion
|
Small Bowel Water Content (SBWC) in millilitres(mL) measured by MRI
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve (mL.min) will be calculated from hourly MRI scans
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Small Bowel Water Content (SBWC) in millilitres measured by MRI
Time Frame: Baseline, 60 minutes before test meal
|
After 5 days of taking the study product participants will undergo an MRI scan while fasted.
|
Baseline, 60 minutes before test meal
|
Ascending Colon Water Content in millilitres measured by MRI
Time Frame: Baseline, 60 minutes before test meal
|
After 5 days taking study product participants will undergo an MRI scan while fasted
|
Baseline, 60 minutes before test meal
|
Ascending Colon Water Content in millilitres measured by MRI
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve (mL.min) will be calculated from hourly MRI scans
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Change from baseline in Ascending Colon Water Content in millilitre measured by MRI
Time Frame: test meal -60, test meal +60
|
Difference between measurement Meal -60 (fasting) and Meal +60
|
test meal -60, test meal +60
|
Change from before to after challenge meal in Ascending Colon Water Content before in millilitre measured by MRI
Time Frame: test meal +360 minutes, test meal + 420 minutes
|
Difference between time points Meal2 -20 and Meal 2 +40
|
test meal +360 minutes, test meal + 420 minutes
|
Ascending Colon T1
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve of MRI parameter measured at hourly time points
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Descending Colon T1
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve of MRI parameter measured at hourly time points
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Ascending colon T2
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve of MRI parameter measured at hourly time points
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Descending Colon T2
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve of MRI parameter measured at hourly time points
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Colonic volume
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve (mL.min) will be measured from hourly MRI scans by segmentation into ascending colon (AC), transverse colon (TC) and descending colon (DC)
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Colonic gas volume
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve (mL.min), measured on hourly MRI scans by segmentation into AC, TC and DC
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Gastric volume
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Area under the curve (mL.min) measured on hourly MRI scans
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Abdominal circumference
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Measured at the umbilicus in cm, determined by MRI
|
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Change from baseline of stool water content percentage by mass
Time Frame: after an average 5 days of intervention
|
Stool will be sampled during the baseline week and between days 3-7 of the intervention week during each treatment period
|
after an average 5 days of intervention
|
Change from baseline in stool frequency
Time Frame: during days 9-14 of treatment period
|
Each treatment period includes 1 day washout, 7 days baseline, up to 7 (minimum 6) days intervention. Total = 15 days. Stool frequency will be sampled on days 2-8 and 9-14, since participants may stop taking intervention before day 15. |
during days 9-14 of treatment period
|
Change from baseline in stool consistency
Time Frame: During days 9-14 of treatment period
|
Each treatment period includes 1 day washout, 7 days baseline, up to 7 (minimum 6) days intervention. Total = 15 days. Stool consistency will be sampled on days 2-8 and 9-14, since participants may stop taking intervention before day 15. |
During days 9-14 of treatment period
|
Change from baseline in faecal microbiota
Time Frame: Change from baseline after an average 5 days of intervention
|
Will be assessed for relative abundance, richness and diversity
|
Change from baseline after an average 5 days of intervention
|
Change from baseline in faecal short-chain fatty acids
Time Frame: Change from baseline after an average 5 days of intervention
|
Stool samples collected during baseline week and after 3 or more days of intervention in each treatment period.
|
Change from baseline after an average 5 days of intervention
|
Symptoms during study day
Time Frame: -60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
4 symptoms will be measured on 2 scales: a previously validated questionnaire on an ordinal scale (OS) of 0 (none), 1 (mild/ distinct but negligible), 2 (moderate/ annoying), 3 (severe/ disabling); and a Visual Analogue Scale (VAS) (0-100) Symptoms include abdominal pain, bloating, gas/flatulence, and diarrhoea. Clinically important symptoms will be defined as additive total score of 3 or greater on OS. VAS scores will be analysed alongside MRI data |
-60, 0, 60, 120, 180, 240, 300, 360, 420 minutes after test meal
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Robin Spiller, MSc MD FRCP, University of Nottingham
- Principal Investigator: Giles Major, BM BCh MRCP, University of Nottingham
- Study Director: Luca Marciani, MSc PhD, University of Nottingham
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UON14011
- 14GA006 (OTHER: Nottingham University Hospitals NHS Trust)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
Chulalongkorn UniversityNot yet recruitingFunctional ConstipationThailand
-
Min-Tze LIONGDeyang People's HospitalRecruiting
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional ConstipationUnited States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
-
University of AlexandriaRecruitingFunctional ConstipationEgypt
Clinical Trials on Maltodextrin
-
Northwestern UniversityUniversity of Illinois at ChicagoActive, not recruitingParkinson Disease | Dietary Modification | Intestinal Bacteria Flora DisturbanceUnited States
-
University of BathUniversity of BirminghamCompleted
-
NestléCompleted
-
University of FoggiaCasa Sollievo della Sofferenza IRCCSActive, not recruitingCesarean Section ComplicationsItaly
-
Columbia UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHIV | Breast Feeding | Infant MorbiditySouth Africa
-
Biofortis, Merieux NutriSciencesLonza Inc.CompletedGut MicrobiotaUnited States
-
SyralBiofortis Mérieux NutriSciences; CreaBio Rhone-AlpesCompletedHealthy | Functional ConstipationFrance
-
Nanjing PLA General HospitalCompletedIrritable Bowel Syndrome
-
NestléCompletedSeasonal Allergic RhinitisSwitzerland
-
NestléCompletedCeliac Disease | Non-celiac Gluten SensitivityNetherlands